Our Pricing

Understanding Wegovy Side Effects: A Complete UK Clinical Guide

Wegovy side effects are a common concern for patients considering this semaglutide weight loss injection, and understanding what to expect is essential for treatment success. As UK pharmacists who have supported thousands of patients through their Wegovy journey, we've seen that whilst most side effects are mild and temporary, knowing how to manage them makes a significant difference to adherence and outcomes. This guide provides expert clinical insight into every aspect of Wegovy's side effect profile, backed by STEP trial data and real-world UK prescribing experience.

Most Common Wegovy Side Effects Reported in UK Patients

The most frequently reported Wegovy side effects involve the gastrointestinal system, affecting approximately 44% of patients in the STEP clinical trial programme[1]. Nausea is the single most common reaction, typically occurring when starting treatment or increasing the dose, and usually resolves within 2-4 weeks as your body adapts to the medication. Other prevalent digestive symptoms include diarrhoea (30% of patients), constipation (24%), vomiting (24%), and abdominal discomfort (20%)[1].

In our clinical experience at Cured Pharmacy, these Wegovy side effects are dose-dependent and can be significantly minimised through proper management strategies. Superintendent pharmacist Tarun Kumar (GPhC 2233073) advises that patients who follow the gradual dose escalation schedule and implement dietary modifications experience notably fewer severe symptoms. The MHRA-approved titration schedule starts at 0.25mg weekly, allowing your body to adjust before reaching the maintenance dose of 2.4mg[2].

Gastrointestinal Wegovy Side Effects: Timeline and Severity

Understanding the timeline of Wegovy side effects helps set realistic expectations. Nausea typically peaks within 24-72 hours after injection and diminishes over the following days. Most patients report that digestive side effects are most pronounced during the first 8-12 weeks of treatment, particularly during dose escalation phases. Clinical data shows that by week 20, the incidence of nausea drops to below 10%, and many patients report complete resolution[1].

The severity of Wegovy side effects varies considerably between individuals. In the STEP trials, only 4.5% of patients discontinued treatment due to gastrointestinal adverse events, indicating that whilst common, these effects are manageable for the vast majority[1]. We recommend taking Wegovy with a small meal, staying well-hydrated, and avoiding high-fat foods on injection days to minimise digestive discomfort.

Serious Wegovy Side Effects Requiring Medical Attention

Whilst rare, certain Wegovy side effects require immediate medical assessment. Acute pancreatitis occurred in 0.2% of patients in clinical trials, presenting as severe upper abdominal pain radiating to the back, often accompanied by nausea and vomiting[2]. If you experience persistent severe abdominal pain, you should stop Wegovy immediately and contact your prescriber or attend A&E.

Gallbladder problems, including cholelithiasis (gallstones), represent another serious category of Wegovy side effects, affecting approximately 1.6% of patients in the STEP programme[1]. Rapid weight loss itself increases gallstone risk, and semaglutide may compound this effect. Symptoms include sudden right upper abdominal pain, particularly after fatty meals, fever, and jaundice. Thyroid tumours were observed in animal studies, and whilst no causal link has been established in humans, Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2[2].

Hypoglycaemia is an uncommon Wegovy side effect in patients without diabetes, but those taking concurrent diabetes medications may experience low blood sugar. The MHRA advises careful monitoring and potential dose adjustment of sulfonylureas or insulin when initiating Wegovy[2]. Symptoms include shakiness, sweating, confusion, and rapid heartbeat.

Managing Wegovy Side Effects: Evidence-Based Strategies

Effective management of Wegovy side effects significantly improves treatment adherence and outcomes. For nausea, the most troublesome symptom, we recommend eating smaller, more frequent meals rather than three large ones, avoiding lying down immediately after eating, and choosing bland, low-fat foods during the first weeks of each new dose. Ginger tea and staying upright for at least an hour post-injection can provide additional relief.

Constipation-related Wegovy side effects respond well to increased fibre intake (25-30g daily), adequate hydration (2-3 litres of water daily), and regular physical activity. If dietary measures prove insufficient, bulk-forming laxatives like ispaghula husk are safe to use alongside Wegovy. For diarrhoea, reducing dietary fat, avoiding dairy temporarily, and ensuring electrolyte replacement through oral rehydration solutions helps maintain comfort whilst your body adjusts[3].

Dietary Modifications to Reduce Wegovy Side Effects

Specific dietary changes can substantially reduce Wegovy side effects. Avoiding high-fat meals is particularly important, as semaglutide delays gastric emptying and fatty foods exacerbate nausea and bloating. Focus on lean proteins, complex carbohydrates, and vegetables, introducing foods gradually if you've been experiencing symptoms. Alcohol can worsen gastrointestinal Wegovy side effects and should be limited, especially during dose escalation periods.

Timing your injection strategically also helps manage Wegovy side effects. Many patients find that injecting on Friday evening allows them to rest over the weekend when symptoms may be most pronounced. Taking the injection after a light meal, rather than on an empty stomach, can reduce initial nausea for some individuals, though this varies between patients.

Wegovy Side Effects Compared to Other Weight Loss Treatments

When comparing Wegovy side effects to alternative weight loss medications, the GLP-1 agonist class shows a distinct side effect profile. Mounjaro (tirzepatide), which combines GLP-1 and GIP receptor agonism, demonstrates similar gastrointestinal side effects but some data suggests potentially greater nausea rates at equivalent weight loss efficacy[4]. However, individual tolerance varies significantly, and some patients who struggle with Wegovy side effects tolerate Mounjaro better, and vice versa.

Orlistat-based treatments like Xenical produce entirely different side effects, primarily gastrointestinal effects related to fat malabsorption including oily stools, flatulence, and faecal urgency. Whilst these occur in up to 20% of users, they're mechanistically distinct from Wegovy side effects and can be controlled through dietary fat restriction[5]. Saxenda (liraglutide), another GLP-1 agonist requiring daily injection, shows comparable Wegovy side effects but with potentially higher discontinuation rates due to injection frequency burden.

Mysimba, combining naltrexone and bupropion, presents a different side effect spectrum including nausea (32%), headache, and constipation, but also carries risks of increased blood pressure and psychiatric effects not seen with Wegovy[5]. The choice between treatments depends on individual tolerance, medical history, and preference regarding injection frequency versus side effect profile.

Long-Term Wegovy Side Effects and Safety Data

Long-term Wegovy side effects data from the STEP extension studies, following patients for up to 104 weeks, demonstrates that most adverse events occur during the initial titration phase and diminish substantially over time[1]. Gastrointestinal side effects, which dominate the early treatment period, show marked reduction after 6 months of treatment. The overall discontinuation rate due to adverse events remained low at 6.8% across the full study duration, suggesting good long-term tolerability.

Cardiovascular safety data for Wegovy side effects is particularly reassuring. The SELECT trial, involving over 17,000 patients followed for an average of 40 months, demonstrated a 20% reduction in major adverse cardiovascular events compared to placebo, with no safety signals emerging during extended follow-up[6]. This data supports Wegovy's safety profile for long-term use in appropriate patients under medical supervision.

Concerns about potential long-term Wegovy side effects on bone density, particularly given rapid weight loss, have been investigated in sub-studies. Whilst weight loss generally reduces bone mineral density, semaglutide does not appear to accelerate this beyond what's expected from weight reduction itself[3]. Patients are advised to ensure adequate calcium and vitamin D intake, particularly if treatment extends beyond one year.

Monitoring for Wegovy Side Effects During Treatment

Regular monitoring helps identify Wegovy side effects early and ensures safe continuation of treatment. At Cured Pharmacy, our UK-registered clinical team conducts follow-up assessments at 4-week intervals during the first 3 months, then 12-weekly thereafter. We monitor weight loss progress, side effect severity, and any emerging concerns that might require dose adjustment or additional support.

Blood pressure and heart rate should be checked periodically, as Wegovy can increase resting heart rate by an average of 2-3 beats per minute[2]. Patients with pre-existing cardiovascular conditions require closer monitoring. If you experience persistent Wegovy side effects that significantly impact quality of life, your prescriber may recommend temporarily maintaining your current dose rather than escalating, or in some cases, stepping back to the previous dose level until symptoms resolve.

When Wegovy Side Effects Indicate Treatment Discontinuation

Certain Wegovy side effects warrant treatment discontinuation. Severe, persistent vomiting leading to dehydration despite management strategies requires stopping treatment and seeking medical assessment. Similarly, signs of pancreatitis (severe abdominal pain radiating to the back), gallbladder inflammation (right upper quadrant pain with fever), or allergic reactions (facial swelling, difficulty breathing, severe rash) necessitate immediate cessation and medical attention[2].

Psychiatric Wegovy side effects, though uncommon, require careful evaluation. The MHRA has noted reports of suicidal ideation in a small number of patients taking GLP-1 agonists, though causality remains unclear[2]. If you experience new or worsening depression, suicidal thoughts, or significant mood changes, contact your prescriber immediately. Pregnancy is an absolute contraindication for Wegovy, and treatment must stop immediately if you become pregnant, as semaglutide crosses the placental barrier.

However, it's important to distinguish between manageable Wegovy side effects and those requiring discontinuation. Mild nausea, occasional loose stools, or temporary appetite reduction during dose escalation are expected and typically resolve with time and management strategies. At Cured Pharmacy, our clinical team provides ongoing support to help you navigate side effects and optimise your treatment journey. Wegovy is available from £69.00 subject to prescriber approval, with transparent pricing and comprehensive clinical support throughout your treatment.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 15 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Wadden, T. A. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
5. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management. Clinical guideline [CG189]. NICE. [accessed 15 August 2026]
6. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. [accessed 15 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.